You are here

Sangamo Therapeutics

Sangamo to lay off 120 as it pares pipeline

Sangamo to lay off 120 as it pares pipeline

BioPharma Dive

Sangamo Therapeutics

Flag link:

Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo

Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo

BioSpace

Sangamo Therapeutics

gene regulation therapies

Flag link:

Another Pfizer gene therapy is free of FDA hold, but delay continues

Another Pfizer gene therapy is free of FDA hold, but delay continues

Fierce Biotech

clinical trials

giroctocogene fitelparvovec

Sangamo Therapeutics

Flag link:

Sanofi cuts ties with Sangamo, sharpening focus on 'off-the-shelf' cell therapy

Sanofi cuts ties with Sangamo, sharpening focus on 'off-the-shelf' cell therapy

BioPharma Dive

Sangamo Therapeutics

sickle cell disease

Flag link:

Sangamo's Fabry gene therapy clears early clinical test, firing starting gun on preparations for phase 3

Sangamo's Fabry gene therapy clears early clinical test, firing starting gun on preparations for phase 3

Fierce Biotech

Sangamo Therapeutics

clinical trials

Flag link:

Pfizer tears up gene therapy timelines, revealing a series of phase 3 delays that end vision of a banner 2022

Pfizer tears up gene therapy timelines, revealing a series of phase 3 delays that end vision of a banner 2022

Fierce Biotech

Duchenne Muscular Dystrophy

Sangamo Therapeutics

Flag link:

Gene therapy for Fabry: early stages, promising results

Gene therapy for Fabry: early stages, promising results

BioPharma Dive

Freeline Therapeutics

Sangamo Therapeutics

Flag link:

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525

Drugs.com

Sangamo Therapeutics

clinical trials

giroctocogene fitelparvovec

Flag link:

Sangamo and Novartis Enter Agreement to Focus on Neurodevelopmental Diseases

Sangamo and Novartis Enter Agreement to Focus on Neurodevelopmental Diseases

BioSpace

Sangamo Therapeutics

gene regulation therapies

neurodevelopmental disorders

Flag link:

Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%

Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%

Motley Fool

Sangamo Therapeutics

Parkinson's Disease

Alzheimer's disease

Flag link:

Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease

Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease

Motley Fool

beta thalassemia

drug development

Bristol-Myers Squibb

Sangamo Therapeutics

Vertex Pharmaceuticals

Editas Medicine

Syros Pharmaceuticals

Flag link:

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Yahoo/Benzinga

Sangamo Therapeutics

Catalyst Biosciences

Reata Pharmaceuticals

Vertex Pharmaceuticals

Gilead Sciences

TRACON Pharmaceuticals

Sorrento Therapeutics

Flag link:

Does Sangamo Have the Best Gene Therapy Program Now?

Does Sangamo Have the Best Gene Therapy Program Now?

Motley Fool

Sangamo Therapeutics

Flag link:

Should Sangamo's Failure Make CRISPR Investors Nervous?

Should Sangamo's Failure Make CRISPR Investors Nervous?

Motley Fool

Sangamo Therapeutics

CRISPR Therapeutics

Editas Medicine

Flag link:

Cutting-edge biotech Sangamo stock dives 12% after JPMorgan cites ‘growing skepticism’ in downgrade

Cutting-edge biotech Sangamo stock dives 12% after JPMorgan cites ‘growing skepticism’ in downgrade

Marketwatch

Sangamo Therapeutics

Flag link:

Sangamo falls on 16-week data from gene editing trial

Sangamo falls on 16-week data from gene editing trial

BioCentury

Sangamo Therapeutics

Hunter Syndrome

Flag link:

Highly anticipated trial results expected soon could move all three of these biotechs

Highly anticipated trial results expected soon could move all three of these biotechs

Motley Fool

Sangamo Therapeutics

Esperion Therapeutics

Flag link:

3 Biotech Stocks With Major Catalysts Incoming

3 Biotech Stocks With Major Catalysts Incoming

Motley Fool

TG Therapeutics

Sangamo Therapeutics

Akcea Therapeutics

Flag link:

Demand For Gene Therapies To Prompt Surge In Pharma M&A

Demand For Gene Therapies To Prompt Surge In Pharma M&A

Forbes

Sangamo Therapeutics

Flag link:

[video]Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important

[video]Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important

Motley Fool

Sangamo Therapeutics

Flag link:

Pages